Cadrenal Therapeutics Files 8-K Report
Ticker: CVKD · Form: 8-K · Filed: Oct 24, 2024 · CIK: 1937993
Sentiment: neutral
Topics: 8-k, disclosure, financials
Related Tickers: CADRN
TL;DR
CADRN filed an 8-K today covering financials and other events.
AI Summary
On October 24, 2024, Cadrenal Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. The company is incorporated in Delaware and its principal executive offices are located in Ponte Vedra, Florida.
Why It Matters
This 8-K filing provides important updates and disclosures from Cadrenal Therapeutics, Inc. to investors and the public.
Risk Assessment
Risk Level: low — This filing is a routine disclosure and does not appear to contain significant negative news or events.
Key Players & Entities
- Cadrenal Therapeutics, Inc. (company) — Registrant
- October 24, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 822 A1A North , Suite 306 Ponte Vedra , Florida 32082 (address) — Principal Executive Offices
- 904-300-0701 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Cadrenal Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on Other Events, Financial Statements and Exhibits, and to provide a Regulation FD Disclosure.
When was this 8-K report filed by Cadrenal Therapeutics, Inc.?
This 8-K report was filed on October 24, 2024.
In which state is Cadrenal Therapeutics, Inc. incorporated?
Cadrenal Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Cadrenal Therapeutics, Inc.?
The business address of Cadrenal Therapeutics, Inc. is 822 A1A North, Suite 306, Ponte Vedra, Florida 32082.
What is the telephone number for Cadrenal Therapeutics, Inc.?
The telephone number for Cadrenal Therapeutics, Inc. is (904) 300-0701.
Filing Stats: 704 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2024-10-24 09:10:06
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CVKD The Nasdaq Stock Mar
- $13.15 — on stock at a weighted average price of $13.15 per share, generating gross proceeds of
- $5.1 million — erating gross proceeds of approximately $5.1 million through its at-the-market ("ATM") facil
Filing Documents
- ea0218502-8k_cadrenal.htm (8-K) — 29KB
- ea021850201ex99-1_cadrenal.htm (EX-99.1) — 8KB
- 0001213900-24-090153.txt ( ) — 212KB
- cvkd-20241024.xsd (EX-101.SCH) — 3KB
- cvkd-20241024_lab.xml (EX-101.LAB) — 33KB
- cvkd-20241024_pre.xml (EX-101.PRE) — 22KB
- ea0218502-8k_cadrenal_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On October 24, 2024, Cadrenal Therapeutics, Inc., a Delaware corporation (the "Company"), issued a press release regarding the sale of 391,243 shares of common stock at a weighted average price of $13.15 per share, generating gross proceeds of approximately $5.1 million through its at-the-market ("ATM") facility. Following the completion of the sales under the ATM facility, the Company has 1,496,771 shares of common stock outstanding as of October 23, 2024. The information in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.
01. Other Events
Item 8.01. Other Events. On October 24, 2024, the Company issued a press release regarding the sale of 391,243 shares of common stock at a weighted average price of $13.15 per share, generating gross proceeds of approximately $5.1 million through its ATM facility. Following the completion of the sales under the ATM facility, the Company has 1,496,771 shares of common stock outstanding as of October 23, 2024.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are furnished with this Current Report on Form 8-K: Exhibit Number Exhibit Description 99.1 Press Release, issued by Cadrenal Therapeutics, Inc. on October 24, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 24, 2024 CADRENAL THERAPEUTICS, INC. By: /s/ Quang Pham Name: Quang Pham Title: Chairman and Chief Executive Officer 2